Researcher profile

Mary‐Ellen Taplin

Unclaimed researcher profile imported from scholarly metadata

ORCID

Publications

Citations

H-index

Recent H-index

Reads

Followers

Overview

Research identity

Research areas

Not available

Education

Not available

Research

Research outputs

Public works are drawn from admitted ResearchHub scholarly records.

Publications

Selected public works

Search public worksYearWork typeSort works

14 of 14 listed works

Exports contain available public metadata for the works currently shown.

Data from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 8 reads

Figure 1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 7 reads

Figure 2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Figure 3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 8 reads

Figure 4 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Supplementary Figure S1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Supplementary Figure S2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Supplementary Figure S3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 8 reads

Supplementary Table S1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 8 reads

Supplementary Table S2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Supplementary Table S3 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Supplementary Table S4 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 7 reads

Table 1 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 9 reads

Table 2 from A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

2026 · posted-content

0 citations · 6 reads

Mary‐Ellen Taplin

Research identity

Research areas

Education

Research outputs

Selected public works

Public projects

Public datasets

Questions & answers